Navigation Links
Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
Date:12/5/2013

ANAHEIM, Calif., Dec. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Oppenheimer 24th Annual Healthcare Conference in New York City on December 11, 2013 at 8:20 AM  ET/5:20 AM PT.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. 

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following approved indications: the treatment of proteinuria in the nephrotic syndrome (NS) of the idiopathic type, the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of certain rheumatology related conditions, and the treatment of infantile spasms (IS) in infants and children under two years of age. With respect to NS, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis. The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States. For more information about Questcor, please visit www.questcor.com.   


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
2. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
3. Questcor Honored as an "Everyday Hero" by NephCure Foundation
4. Questcor Adds G. Kelly Martin to Board of Directors
5. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
6. Questcor Reports Third Quarter Financial Results
7. Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
8. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
9. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
10. Questcor to Commence Phase 2 Study of Acthar for ALS
11. Questcor to Report Second Quarter Financial Results on July 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star Insurance ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. ... removal surgery at their office. Wisdom tooth removal, a common dental procedure, is performed ... they often are improperly erupted, resulting in risks of complications. By providing wisdom tooth ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Francesca Loparco, ... changed her life forever with a same-day LASIK procedure at Christenbury Eye ... eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her in-office consultation ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Warren L. Smith ... infections, also called UTIs, have plagued people since the beginning of recorded medical ... get bladder infections every year. It's not just a matter of inconvenience; bladder infections ...
Breaking Medicine News(10 mins):